SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...
SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...
* This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the th...
SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...
* XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. * XPOVIO® has been approv...
SHANGHAI and HONG KONG, Aug. 23, 2024 /PRNewswire/ -- Antengene Corporation (6996.HK) today announc...
* XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia. * XPOVIO® has been approv...
- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM)...
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health I...
* Oral Presentation：a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody ...
* Oral session：ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for c...
SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...
* Promising clinical activities and efficacies during dose escalations for four lead global right...
SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...
SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...
* The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) a...
SHANGHAI and HONG KONG, Dec. 14, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...
* The Phase I PERFORM trial, taking place at four clinical trial centers across the U.S., will ev...
* XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau. * X...
* Clinical programs, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 a...